Kausik K. Ray, United Kingdom

Imperial College London Centre for Primary Care and Public Health
Kausik Ray is Professor of Public Heath, Consultant Cardiologist, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials in the School of Public Health, Imperial College London, and President-Elect of the European Atherosclerosis Society. Listed in Clarivate Analytics' list of the top 1% Highly Cited Researchers in medicine globally in 2018 and 2019, he has an H index of 80, an i10 of 199 and over 82,000 citations. Key contributions have influenced European and American guidelines, his work on statins and diabetes risk having led to a global label change for statins by the FDA and EMEA. He is involved in 8 trials in lipids and diabetes and is PI for ORION 1, 3, 11 and BETonMACE. He leads the EAS FH Studies Collaboration, the first global registry of FH with 70 countries and 62,000 cases, and is Senior PI for the TOGETHER study looking at cardiometabolic risk in vascular health checks in 250,000 people. His research focuses on preventing coronary disease, specifically lipids, diabetes, biomarkers, and risk prediction.

Presenter Of 12 Presentations

Panel Discussion with Live Q&A

Session Type
CME Session
Date
07.10.2020, Wednesday
Session Time
17:30 - 19:00
Lecture Time
18:33 - 18:48

Webcast

[session]
[presentation]
[presenter]
Hide

Lessons from the DA VINCI study

Session Type
Industry Sponsored Session
Date
07.10.2020, Wednesday
Session Time
14:30 - 16:00
Lecture Time
14:30 - 14:36

Webcast

[session]
[presentation]
[presenter]
Hide

Live Q&A

Webcast

[session]
[presentation]
[presenter]
Hide

PCSK9 inhibitors; what can we learn from 5 years of real-world experience?

Session Type
Industry Sponsored Session
Date
07.10.2020, Wednesday
Session Time
14:30 - 16:00
Lecture Time
15:12 - 15:28

Webcast

[session]
[presentation]
[presenter]
Hide

LIVE Panel discussion: with a focus on very-high risk patients

Session Type
Industry Sponsored Session
Date
07.10.2020, Wednesday
Session Time
14:30 - 16:00
Lecture Time
15:28 - 15:53

Webcast

[session]
[presentation]
[presenter]
Hide

siRNA based approaches targeting hepatic synthesis of PCSK9

Session Type
CME Session
Date
07.10.2020, Wednesday
Session Time
17:30 - 19:00
Lecture Time
18:13 - 18:33

Webcast

[session]
[presentation]
[presenter]
Hide

Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: Analysis from the Phase III ORION-11 trial

Session Name
Session Type
Late breaker
Date
05.10.2020, Monday
Session Time
16:00 - 17:00
Lecture Time
16:07 - 16:14

Webcast

[session]
[presentation]
[presenter]
Hide

What do we know so far about bempedoic acid?

Session Type
CME Session
Date
04.10.2020, Sunday
Session Time
17:00 - 18:30
Lecture Time
17:31 - 17:45

Webcast

[session]
[presentation]
[presenter]
Hide

Panel Discussion with Live Q&A

Session Type
CME Session
Date
04.10.2020, Sunday
Session Time
17:00 - 18:30
Lecture Time
17:45 - 18:00

Webcast

[session]
[presentation]
[presenter]
Hide

Lipid lowering therapy in primary and secondary prevention across Europe: are LDL-C goals achieved? Results from the DA VINCI study

Session Type
Track 4 - Prevention and Treatment of CVD
Date
06.10.2020, Tuesday
Session Time
10:00 - 11:13
Lecture Time
10:20 - 10:30

Abstract

Background and Aims

Describe lipid lowering therapy (LLT) and achievement of the LDL-C goals recommended in 2016 EAS/ESC dyslipidaemia guidelines.

Methods

Cross-sectional observational study in 18 European countries. Data were collected at a single visit for adults seen in primary or secondary care who consented to participate, with any LLT in the past 12 months and an LDL-C measurement in the past 14 months. FH patients with a prior CV event were ineligible. LLT, most recent LDL-C and clinical/demographic characteristics were abstracted from medical notes. Primary outcome was LDL-C goal attainment ≥ 28 days after starting the most recent LLT (treatment stabilised LLT).

Results

Between Jun ‘17–Nov ’18, 5888 eligible subjects were enrolled. Approximately half (3000 [51%]) were primary prevention (PP). Of 2888 secondary prevention subjects, 2794 met our definition of ASCVD: 22% (622) had coronary disease, 41% (1136) cerebral and 37% (1036) peripheral. 2558 PP and 2039 ASCVD subjects had a treatment stabilised LDL-C; median, 93 and 77 mg/dL, respectively. Among subjects at highest CV risk, 21% of 89 very-high-risk PP and 39% of 2039 ASCVD achieved the recommended LDL-C goal of 70 mg/dL. Among 448 PP and 858 ASCVD subjects receiving high intensity statins, 68% and 46% reached goal, respectively. Among 952 ASCVD subjects receiving moderate intensity statins, 36% achieved goal. Over half (54%) of ASCVD subjects received sub-optimal (low/moderate intensity) statin therapy.

Conclusions

These data highlight a large gap between 2016 ESC/EAS treatment recommendations and European clinical practice across a broad range of patients eligible for LLT.

Hide

Webcast

[session]
[presentation]
[presenter]
Hide

Risk stratification in very high risk patients is it of value?

Session Type
CME Session
Date
05.10.2020, Monday
Session Time
14:00 - 15:30
Lecture Time
14:27 - 14:51

Webcast

[session]
[presentation]
[presenter]
Hide

Panel Discussion with Live Q&A

Session Type
CME Session
Date
05.10.2020, Monday
Session Time
14:00 - 15:30
Lecture Time
15:15 - 15:30

Webcast

[session]
[presentation]
[presenter]
Hide